Difluprednate

Difluprednate

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a609025
License data	US FDA: Difluprednate
Routes of administration	topical dermatologic
ATC code	D07AC19 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
CAS Number	23674-86-4 Y
PubChem CID	32037
DrugBank	DB06781 N
ChemSpider	391990 N
UNII	S8A06QG2QE
KEGG	D01266 Y
ChEMBL	CHEMBL1201749 N
ECHA InfoCard	100.041.636
Chemical and physical data
Formula	C27H34F2O7
Molar mass	508.551
NY (what is this?)

Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain. It is marketed by Alcon under the tradename Durezol.

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.

...
Wikipedia